Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.72 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA3 | P07451 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA6 | P23280 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 3/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9645456 | 1.00 | PRMT5 (0.72) | PRMT5WDR77PKMALDH1A1LMNA | |
| SCHEMBL2967442 | 1.00 | PRMT5 (0.72) | PRMT5WDR77PKMALDH1A1LMNA | |
| SCHEMBL30301224 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL336605 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL336603 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL29481767 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL449928 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL29476299 | 0.84 | PRMT5 (1.00) | PRMT5WDR77ALDH1A1LMNAGAA | |
| SCHEMBL9303799 | 0.83 | PRMT5 (0.53) | PRMT5WDR77PKMALDH1A1CA2 | |
| SCHEMBL7470093 | 0.83 | PRMT5 (0.67) | PRMT5WDR77PKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303474-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | ACTIMED THERAPEUTICS LIMITED (GB) | 2025-05-20 | — | — | US | disclosed |
| US-20250135022-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MACROGENICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4476262-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MacroGenics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240325322-A1 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | ACTIMED THERAPEUTICS LTD (GB) | 2024-10-03 | — | — | US | disclosed |
| WO-2024178155-A1 | TRANS-CYCLOOCTENE CONJUGATES | TAMBO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-118290358-A | Method for preparing linezolid key intermediate (S) -5- ((benzylamino) methyl) oxazolidine-2-one | 江苏医药职业学院 | 2024-07-05 | — | — | CN | disclosed |
| US-11938102-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | ACTIMED THERAPEUTICS LIMITED (GB) | 2024-03-26 | — | — | US | disclosed |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023154784-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MACROGENICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20120142928-A1 | PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-07 | — | — | US | disclosed |
| WO-2011019842-A1 | PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | WO | disclosed |
| CN-1984906-A | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC (JP) | 2007-06-20 | — | — | CN | disclosed |
| CN-1164574-C | Phenoxypropylamine compounds | ������ҩ��ʽ���� | 2004-09-01 | — | — | CN | disclosed |
| CN-1139586-C | Process for stereoselective preparation of hetero-bicyclic alcohol enantiomer | �ŷƶ����ʿ�������˾ | 2004-02-25 | — | — | CN | disclosed |
| CN-1378533-A | Phenoxypropylamine compounds | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-11-06 | — | — | CN | disclosed |
| WO-2002005804-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| CN-1160714-A | Process for stereoselective preparation of hetero-bicyclic alcohol enantiomer | DUPHAR INT RES (NL) | 1997-10-01 | — | — | CN | disclosed |
| EP-0512020-A1 | PROCESS FOR PREPARING HOMOCHIRAL AMINES AND PROCESS FOR PREPARING INTERMEDIATES FOR THE PREPARATION THEREOF | Nobel Chemicals AB (SE) | 1992-11-11 | — | — | EP | disclosed |
| WO-1991010642-A1 | PROCESS FOR PREPARING HOMOCHIRAL AMINES AND PROCESS FOR PREPARING INTERMEDIATES FOR THE PREPARATION THEREOF, AND THE INTERMEDIATES PREPARED IN ACCORDANCE WITH THIS PROCESS | NOBEL CHEMICALS AB (SE) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303474-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | SMN1; SMN2, CPT1B, ADRB1 | PRMT5 2446/4885WDR77 755/4885PKM 3652/4885 |
| US-20250135022-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | CD274, PDCD1LG2, PDCD1 | PRMT5 3180/4885WDR77 2303/4885PKM 3221/4885 |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | PRMT5 1558/4885WDR77 1929/4885PKM 4782/4885 |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | CD274, PDCD1, H1-3 | PRMT5 1358/4885WDR77 2116/4885PKM 3181/4885 |
| US-20120142928-A1 | PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS | CTSS, CTSB, CTSF | PRMT5 3631/4885WDR77 4146/4885PKM 2840/4885 |
| US-11938102-B2 | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | SMN1; SMN2, CPT1B, ADRB1 | PRMT5 2446/4885WDR77 755/4885PKM 3652/4885 |
| US-20240325322-A1 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, CPT1B, ADRB1 | PRMT5 2446/4885WDR77 755/4885PKM 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.